Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
NCT05046613
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Migraine
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 0 years and older
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- Pfizer
- Last updated on ClinicalTrials.gov
- May 5, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
North Carolina · 1
- Evidera, a PPD business unit · Wilmington, NC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.